{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:58:09Z","timestamp":1792292289419,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical resection is the cornerstone of treatment. Platinum-based chemotherapy is the standard regimen for advanced TET. Due to the rarity of this disease, treatment decisions should be discussed in specific multidisciplinary tumour boards, and there are few prospective clinical studies with new strategies. However, several pathways involved in TET have been explored as potential targets for new therapies in previously treated patients, such as multi-tyrosine kinase inhibitors with antiangiogenic properties and immune checkpoint inhibitors (ICI). One third of patient with thymoma present an autoimmune disorders, increasing the risk of immune-related adverse events and autoimmune flares under ICIs. In these guidelines, we summarize the current evidence for the therapeutic approach in patients with TET and define levels of evidence for these decisions.\n<\/jats:p>","DOI":"10.1007\/s12094-022-02788-w","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T14:02:49Z","timestamp":1644069769000},"page":"635-645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":false,"given":"J.","family":"Remon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bernab\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Diz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Gonz\u00e1lez-Larriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Mielgo-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Massutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,5]]},"reference":[{"key":"2788_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1086\/321805","volume":"33","author":"CA Dykewicz","year":"2001","unstructured":"Dykewicz CA, Centers for Disease Control and Prevention (U.S.), Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139\u201344. https:\/\/doi.org\/10.1086\/321805.","journal-title":"Clin Infect Dis"},{"key":"2788_CR2","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","volume":"10","author":"A Marx","year":"2015","unstructured":"Marx A, Chan JKC, Coindre J-M, Detterbeck F, Girard N, Harris NL, et al. The 2015 World Health Organization classification of tumors of the thymus: continuity and changes. J Thorac Oncol. 2015;10:1383\u201395. https:\/\/doi.org\/10.1097\/JTO.0000000000000654.","journal-title":"J Thorac Oncol"},{"key":"2788_CR3","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S1470-2045(17)30445-X","volume":"18","author":"G Gatta","year":"2017","unstructured":"Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017;18:1022\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(17)30445-X.","journal-title":"Lancet Oncol"},{"key":"2788_CR4","unstructured":"http:\/\/www.madrid.org\/bvirtual\/BVCM050184.pdf. Acessed 02 Feb\u00a02022"},{"key":"2788_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102014","volume":"86","author":"F Conforti","year":"2020","unstructured":"Conforti F, Pala L, Giaccone G, De Pas T. Thymic epithelial tumors: from biology to treatment. Cancer Treat Rev. 2020;86: 102014. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102014.","journal-title":"Cancer Treat Rev"},{"key":"2788_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1177\/030089160108700411","volume":"87","author":"G De Toma","year":"2001","unstructured":"De Toma G, Plocco M, Nicolanti V, Brozzetti S, Letizia C, Cavallaro A. Type B1 thymoma in multiple endocrine neoplasia type 1 (MEN-1) syndrome. Tumori. 2001;87:266\u20138.","journal-title":"Tumori"},{"key":"2788_CR7","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.3390\/cancers13102472","volume":"13","author":"SS Badve","year":"2021","unstructured":"Badve SS, Dougherty R, Balatico M, Kesler KA, Loehrer P, G\u00f6kmen-Polar Y. Thymic carcinomas and second malignancies: a single-center review. Cancers (Basel). 2021;13:2472. https:\/\/doi.org\/10.3390\/cancers13102472.","journal-title":"Cancers (Basel)"},{"key":"2788_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/JTO.0b013e318276241c","volume":"8","author":"C Mariano","year":"2013","unstructured":"Mariano C, Ionescu DN, Cheung WY, Ali RH, Laskin J, Evans K, et al. Thymoma: a population-based study of the management and outcomes for the province of British Columbia. J Thorac Oncol. 2013;8:109\u201317. https:\/\/doi.org\/10.1097\/JTO.0b013e318276241c.","journal-title":"J Thorac Oncol"},{"key":"2788_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.ejrad.2014.01.005","volume":"83","author":"S Seki","year":"2014","unstructured":"Seki S, Koyama H, Ohno Y, Nishio M, Takenaka D, Maniwa Y, et al. Diffusion-weighted MR imaging vs multi-detector row CT: direct comparison of capability for assessment of management needs for anterior mediastinal solitary tumors. Eur J Radiol. 2014;83:835\u201342. https:\/\/doi.org\/10.1016\/j.ejrad.2014.01.005.","journal-title":"Eur J Radiol"},{"key":"2788_CR10","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.21037\/gs.2019.05.06","volume":"8","author":"F Gentili","year":"2019","unstructured":"Gentili F, Pelini V, Lucii G, Luzzi L, Mazzei FG, Fausto A, et al. Update in diagnostic imaging of the thymus and anterior mediastinal masses. Gland Surg. 2019;8:S188\u2013207. https:\/\/doi.org\/10.21037\/gs.2019.05.06.","journal-title":"Gland Surg"},{"key":"2788_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jasc.2020.04.006","volume":"9","author":"D Suster","year":"2020","unstructured":"Suster D, Suster S. The role of needle core biopsies in the evaluation of thymic epithelial neoplasms. J Am Soc Cytopathol. 2020;9:346\u201358. https:\/\/doi.org\/10.1016\/j.jasc.2020.04.006.","journal-title":"J Am Soc Cytopathol"},{"key":"2788_CR12","doi-asserted-by":"publisher","first-page":"S1078","DOI":"10.1016\/j.annonc.2020.08.1442","volume":"31","author":"JCB Montanez","year":"2020","unstructured":"Montanez JCB, Boucher M-\u00c9, Dansin E, Kerjouan M, Mazieres J, Pichon E, et al. Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET). Ann Oncol. 2020;31:S1078. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.1442.","journal-title":"Ann Oncol"},{"key":"2788_CR13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jtho.2017.11.118","volume":"13","author":"SK Padda","year":"2018","unstructured":"Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, et al. Paraneoplastic syndromes and thymic malignancies: an examination of the international thymic malignancy interest group retrospective database. J Thorac Oncol. 2018;13:436\u201346. https:\/\/doi.org\/10.1016\/j.jtho.2017.11.118.","journal-title":"J Thorac Oncol"},{"key":"2788_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.coi.2010.11.007","volume":"23","author":"MS Anderson","year":"2011","unstructured":"Anderson MS, Su MA. Aire and T cell development. Curr Opin Immunol. 2011;23:198\u2013206. https:\/\/doi.org\/10.1016\/j.coi.2010.11.007.","journal-title":"Curr Opin Immunol"},{"key":"2788_CR15","doi-asserted-by":"publisher","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","volume":"6","author":"FC Detterbeck","year":"2011","unstructured":"Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol. 2011;6:S1710-1716. https:\/\/doi.org\/10.1097\/JTO.0b013e31821e8cff.","journal-title":"J Thorac Oncol"},{"key":"2788_CR16","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","volume":"9","author":"FC Detterbeck","year":"2014","unstructured":"Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, et al. The IASLC\/ITMIG thymic epithelial tumors staging project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014;9:S65-72. https:\/\/doi.org\/10.1097\/JTO.0000000000000290.","journal-title":"J Thorac Oncol"},{"key":"2788_CR17","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.jtho.2017.06.072","volume":"12","author":"A Meurgey","year":"2017","unstructured":"Meurgey A, Girard N, du Vignaux CM, Maury J-M, Tronc F, Thivolet-Bejui F, et al. Assessment of the ITMIG statement on the WHO histological classification and of the eighth TNM staging of thymic epithelial tumors of a series of 188 thymic epithelial tumors. J Thorac Oncol. 2017;12:1571\u201381. https:\/\/doi.org\/10.1016\/j.jtho.2017.06.072.","journal-title":"J Thorac Oncol"},{"key":"2788_CR18","doi-asserted-by":"publisher","first-page":"203636131984169","DOI":"10.1177\/2036361319841696","volume":"11","author":"L Rosell","year":"2019","unstructured":"Rosell L, Wihl J, Hagberg O, Ohlsson B, Nilbert M. Function, information, and contributions: an evaluation of national multidisciplinary team meetings for rare cancers. Rare Tumors. 2019;11:2036361319841696. https:\/\/doi.org\/10.1177\/2036361319841696.","journal-title":"Rare Tumors"},{"key":"2788_CR19","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","volume":"13","author":"CM du Vignaux","year":"2018","unstructured":"du Vignaux CM, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, et al. Systemic therapy in advanced thymic epithelial\u00a0tumors: insights from the RYTHMIC prospective cohort. J Thorac Oncol. 2018;13:1762\u201370. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.005.","journal-title":"J Thorac Oncol"},{"key":"2788_CR20","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.jtho.2017.07.023","volume":"12","author":"C Basse","year":"2017","unstructured":"Basse C, Thureau S, Bota S, Dansin E, Thomas P-A, Pichon E, et al. Multidisciplinary tumor board decision making for postoperative radiotherapy in thymic epithelial tumors: insights from the RYTHMIC prospective cohort. J Thorac Oncol. 2017;12:1715\u201322. https:\/\/doi.org\/10.1016\/j.jtho.2017.07.023.","journal-title":"J Thorac Oncol"},{"key":"2788_CR21","doi-asserted-by":"publisher","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","volume":"26","author":"N Girard","year":"2015","unstructured":"Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, ESMO Guidelines Committee. Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v40\u201355. https:\/\/doi.org\/10.1093\/annonc\/mdv277 (Suppl 5).","journal-title":"Ann Oncol"},{"key":"2788_CR22","doi-asserted-by":"publisher","first-page":"S318","DOI":"10.1097\/JTO.0b013e3181f20dab","volume":"5","author":"FC Detterbeck","year":"2010","unstructured":"Detterbeck FC. Evaluation and treatment of stage I and II thymoma. J Thorac Oncol. 2010;5:S318-322. https:\/\/doi.org\/10.1097\/JTO.0b013e3181f20dab.","journal-title":"J Thorac Oncol"},{"key":"2788_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.athoracsur.2008.03.055","volume":"86","author":"E Davenport","year":"2008","unstructured":"Davenport E, Malthaner RA. The role of surgery in the management of thymoma: a systematic review. Ann Thorac Surg. 2008;86:673\u201384. https:\/\/doi.org\/10.1016\/j.athoracsur.2008.03.055.","journal-title":"Ann Thorac Surg"},{"key":"2788_CR24","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.athoracsur.2006.05.028","volume":"82","author":"CD Wright","year":"2006","unstructured":"Wright CD. Pleuropneumonectomy for the treatment of Masaoka stage IVA thymoma. Ann Thorac Surg. 2006;82:1234\u20139. https:\/\/doi.org\/10.1016\/j.athoracsur.2006.05.028.","journal-title":"Ann Thorac Surg"},{"key":"2788_CR25","doi-asserted-by":"publisher","first-page":"S895","DOI":"10.1016\/j.jtho.2021.08.123","volume":"16","author":"JC Ben\u00edtez","year":"2021","unstructured":"Ben\u00edtez JC, Bluthgen MV, Boucher M, Dansin E, Kerjouan M, Bigay-Game L, et al. Multimodality treatment and outcome in stage III thymic epithelial tumors (TETs): a retrospective analysis from the French RYTHMIC network. J Thorac Oncol. 2021;16:S895\u20136. https:\/\/doi.org\/10.1016\/j.jtho.2021.08.123.","journal-title":"J Thorac Oncol"},{"key":"2788_CR26","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1093\/ejcts\/ezu025","volume":"45","author":"S Hamdi","year":"2014","unstructured":"Hamdi S, Mercier O, Fadel E, Mussot S, Fabre D, Ghigna MR, et al. Is sacrifying the phrenic nerve during thymoma resection worthwhile? Eur J Cardiothorac Surg. 2014;45:e151-155. https:\/\/doi.org\/10.1093\/ejcts\/ezu025.","journal-title":"Eur J Cardiothorac Surg"},{"key":"2788_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jtho.2015.08.004","volume":"11","author":"AJ Friedant","year":"2016","unstructured":"Friedant AJ, Handorf EA, Su S, Scott WJ. Minimally invasive versus open thymectomy for thymic malignancies: systematic review and meta-analysis. J Thorac Oncol. 2016;11:30\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2015.08.004.","journal-title":"J Thorac Oncol"},{"key":"2788_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/JTO.0000000000000128","volume":"9","author":"E Ruffini","year":"2014","unstructured":"Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, et al. Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database. J Thorac Oncol. 2014;9:541\u20138. https:\/\/doi.org\/10.1097\/JTO.0000000000000128.","journal-title":"J Thorac Oncol"},{"key":"2788_CR29","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jtho.2017.01.002","volume":"12","author":"MW Jackson","year":"2017","unstructured":"Jackson MW, Palma DA, Camidge DR, Jones BL, Robin TP, Sher DJ, et al. The impact of postoperative radiotherapy for thymoma and thymic carcinoma. J Thorac Oncol. 2017;12:734\u201344. https:\/\/doi.org\/10.1016\/j.jtho.2017.01.002.","journal-title":"J Thorac Oncol"},{"key":"2788_CR30","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","volume":"15","author":"PJ Loehrer","year":"1997","unstructured":"Loehrer PJ, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol. 1997;15:3093\u20139. https:\/\/doi.org\/10.1200\/JCO.1997.15.9.3093.","journal-title":"J Clin Oncol"},{"key":"2788_CR31","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.athoracsur.2019.11.009","volume":"109","author":"S Kim","year":"2020","unstructured":"Kim S, Bull DA, Hsu C-H, Hsu CC. The role of adjuvant therapy in advanced thymic carcinoma: A National Cancer Database Analysis. Ann Thorac Surg. 2020;109:1095\u2013103. https:\/\/doi.org\/10.1016\/j.athoracsur.2019.11.009.","journal-title":"Ann Thorac Surg"},{"key":"2788_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1183\/09059180.00007312","volume":"22","author":"N Girard","year":"2013","unstructured":"Girard N. Thymic epithelial tumours: from basic principles to individualised treatment strategies. Eur Respir Rev. 2013;22:75\u201387. https:\/\/doi.org\/10.1183\/09059180.00007312.","journal-title":"Eur Respir Rev"},{"key":"2788_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2018.10.018","volume":"126","author":"T Berghmans","year":"2018","unstructured":"Berghmans T, Durieux V, Holbrechts S, Jungels C, Lafitte J-J, Meert A-P, et al. Systemic treatments for thymoma and thymic carcinoma: a systematic review. Lung Cancer. 2018;126:25\u201331. https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.018.","journal-title":"Lung Cancer"},{"key":"2788_CR34","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1111\/1759-7714.13181","volume":"10","author":"X Yang","year":"2019","unstructured":"Yang X, Zhuo M, Shi A, Yang S, Wang Z, Wu M, et al. Optimal first-line treatment for advanced thymic carcinoma. Thorac Cancer. 2019;10:2081\u20137. https:\/\/doi.org\/10.1111\/1759-7714.13181.","journal-title":"Thorac Cancer"},{"key":"2788_CR35","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1097\/JTO.0000000000000370","volume":"9","author":"A Sandri","year":"2014","unstructured":"Sandri A, Cusumano G, Lococo F, Alifano M, Granone P, Margaritora S, et al. Long-term results after treatment for recurrent thymoma: a multicenter analysis. J Thorac Oncol. 2014;9:1796\u2013804. https:\/\/doi.org\/10.1097\/JTO.0000000000000370.","journal-title":"J Thorac Oncol"},{"key":"2788_CR36","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1378\/chest.110.4.1115","volume":"110","author":"PN Lara","year":"1996","unstructured":"Lara PN, Bonomi PD, Faber LP. Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide. Chest. 1996;110:1115\u20137. https:\/\/doi.org\/10.1378\/chest.110.4.1115.","journal-title":"Chest"},{"key":"2788_CR37","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1634\/theoncologist.2019-0593","volume":"25","author":"K Tateishi","year":"2020","unstructured":"Tateishi K, Ko R, Shukuya T, Okuma Y, Watanabe S, Kuyama S, et al. Clinical outcomes of second-line chemotherapy in patients with previously treated advanced thymic carcinoma: a retrospective analysis of 191 patients from the NEJ023 study. Oncologist. 2020;25:e668\u201374. https:\/\/doi.org\/10.1634\/theoncologist.2019-0593.","journal-title":"Oncologist"},{"key":"2788_CR38","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.jtho.2018.07.094","volume":"13","author":"OB Gbolahan","year":"2018","unstructured":"Gbolahan OB, Porter RF, Salter JT, Yiannoutsos C, Burns M, Chiorean EG, et al. A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma. J Thorac Oncol. 2018;13:1940\u20138. https:\/\/doi.org\/10.1016\/j.jtho.2018.07.094.","journal-title":"J Thorac Oncol"},{"key":"2788_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2016.06.020","volume":"99","author":"MV Bluthgen","year":"2016","unstructured":"Bluthgen MV, Boutros C, Fayard F, Remon J, Planchard D, Besse B. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): a single-institution experience. Lung Cancer. 2016;99:111\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2016.06.020.","journal-title":"Lung Cancer"},{"key":"2788_CR40","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2217\/fon.14.144","volume":"10","author":"G Palmieri","year":"2014","unstructured":"Palmieri G, Buonerba C, Ottaviano M, Federico P, Calabrese F, Von Arx C, et al. Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial. Future Oncol. 2014;10:2141\u20137. https:\/\/doi.org\/10.2217\/fon.14.144.","journal-title":"Future Oncol"},{"key":"2788_CR41","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","volume":"33","author":"M Radovich","year":"2018","unstructured":"Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, et al. The integrated genomic landscape of thymic epithelial tumors. Cancer Cell. 2018;33:244-258.e10. https:\/\/doi.org\/10.1016\/j.ccell.2018.01.003.","journal-title":"Cancer Cell"},{"key":"2788_CR42","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","volume":"21","author":"J Sato","year":"2020","unstructured":"Sato J, Satouchi M, Itoh S, Okuma Y, Niho S, Mizugaki H, et al. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol. 2020;21:843\u201350. https:\/\/doi.org\/10.1016\/S1470-2045(20)30162-5.","journal-title":"Lancet Oncol"},{"key":"2788_CR43","doi-asserted-by":"publisher","first-page":"v595","DOI":"10.1093\/annonc\/mdx391.001","volume":"28","author":"JS Ross","year":"2017","unstructured":"Ross JS, Vanden Borre P, Almog N, Schrock AB, Chung J, Vergilio J-A, et al. Comprehensive genomic profiling (CGP) of thymic gland carcinomas. Ann Oncol. 2017;28:v595\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdx391.001.","journal-title":"Ann Oncol"},{"key":"2788_CR44","doi-asserted-by":"publisher","first-page":"S1342","DOI":"10.1016\/j.annonc.2021.08.2147","volume":"32","author":"N Girard","year":"2021","unstructured":"Girard N, Ponce Aix S, Cedres S, Berghmans T, Burgers S, Toffart AC, et al. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. Ann Oncol. 2021;32:S1342. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.2147.","journal-title":"Ann Oncol"},{"key":"2788_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100229","volume":"2","author":"M Ballman","year":"2021","unstructured":"Ballman M, Swift S, Mullenix C, Mallory Y, Zhao C, Szabo E, et al. Tolerability of coronavirus disease 2019 vaccines, BNT162b2 and mRNA-1273, in patients with thymic epithelial tumors. JTO Clin Res Rep. 2021;2: 100229. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100229.","journal-title":"JTO Clin Res Rep"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-022-02788-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T11:34:39Z","timestamp":1649244879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-022-02788-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,5]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2788"],"URL":"https:\/\/doi.org\/10.1007\/s12094-022-02788-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,5]]},"assertion":[{"value":"20 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JR reports advisory board membership from MSD, BMS, BOHERING INGLEHEIM, ASTRAZENECA and OSE-IMMUOTHERAPEUTICS. RBC has nothing to disclose. PDT reports advisory board membership and speaker\u2019s fees from BMS, AstraZeneca, Boehringer Ingelheim, ROCHE, MSD and TAKEDA; grant from AstraZeneca and speaker\u2019s fees from Pfizer and Amgen. EF reports consultant fees or advisory position from AMGEN, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen, Merck Serono, MSD Oncology, Novartis, Pfizer, Roche, Sanofi, Takeda, and Peptomyc. Speaker\u2019s fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Medscape, Merck Sharp & Dohme, Peer Voice, Pfizer, Roche, Takeda and CME Outfitters. Research funding from Fundaci\u00f3n Merck Salud and Merck KGaA. Other Relationship from GRIFOLS. JLGL has nothing to disclose. MLQ reports advisory board membership and speaker\u2019s fees from BMS, MSD, Boehringer Ingelheim, AstraZeneca and Roche. XMR has nothing to disclose. ASH reports and speaker\u2019s fees from BMS and Roche; Advisory board membership from Sanofi, Astra Zeneca, Novartis, Janssen, Takeda and Pfizer. IS reports advisory board membership, speaker\u2019s fees and grants from Roche, Novartis Boehringer Ingelheim; speaker\u2019s fees and grants from Bristol-Myers Squibb, Pfizer and Merck Sharp & Dohme; speaker\u2019s fees and grants from AstraZeneca. BM has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by the any of the authors..","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study informed consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}